-1753360571959.webp&w=3840&q=75)
2025 NOSCM | Immunotherapy in First Line Metastatic Setting
0% Complete
Course Overview
Dr. Eric Singhi reviewed immunotherapy in first-line metastatic settings, noting 30% five-year survival for PDL1 high patients.
Course Content
Course Details
- Duration
- 0.00 hour
- Released
- Jul 25, 2025
- Last Review
- Jul 25, 2025
- Expires
- Jul 25, 2026
Objectives
NA
Target Audience
Physicians
Nurses
Pharmacists
Physician Associates
Faculty & Disclosure
Faculty
Eric K. Singhi, MD
Disclosure
<p>NA</p>
Accreditation
NA
Related Courses
-1769183671548.webp&w=3840&q=75)
2026 MCM | Dealing with Long Term Effects of Breast Cancer Immunotherapy and Targeted Therapy
0.00 AMA PRA Category 1 Credits™
1 Chapter
Immunotherapy
Free
-1769183559393.webp&w=3840&q=75)
2026 MCM | Integrative Medicine and Cancer: How to Improve the Quality of Life and Well Being of Our Patients and Survivors
0.00 AMA PRA Category 1 Credits™
1 Chapter
Immunotherapy
Free